09.2024
European Society for Medical Oncology (ESMO) Congress 2024
Plinabulin/Docetaxel vs. Docetaxel in Survival Benefits of 2L/3L EGFR Wild-Type NSCLC after Platinum Regimens (DUBLIN-3): a Randomized Phase 3 Trial
09.2024
European Society for Medical Oncology (ESMO) Congress 2024
Plinabulin/Docetaxel vs. Docetaxel in Survival Benefits of 2L/3L EGFR Wild-Type NSCLC after Platinum Regimens (DUBLIN-3): a Randomized Phase 3 Trial